Additional Drugs Designated as Voluntary for Highmark’s Medical Injectable Drug Program

Did you know that authenticating via Availity gives you access to all the private information on our website? Login via Availity

Additional Drugs Designated as Voluntary for Highmark’s Medical Injectable Drug Program

For: Professional and Facility Providers

Effective Jan. 1, 2026, Highmark is designating additional drugs as voluntary for the Medical Injectable Drug Program.

Highmark continually evaluates the program and makes changes as appropriate. When drugs are added as voluntary, this means physicians may choose to purchase and bill Highmark directly for those drugs and will receive reimbursement as outlined in the program.

Please use Availity Essentials® to access the proposed rate on the effective date for each drug listed below:

HCPCs

Drug Name

Q5153

Opuviz

Q5147

Pavblu

Q5149

Enzeevu

Q5150

Ahzantive

Q5135

Tyenne IV and SC

Q5098

Imuldosa IV and SC

Q5099

Steqeyma IV and SC

Q5100

Yesintek IV and SC

Q5137

Wezlana SC

Q5138

Wezlana IV

Q9996

Pyzchiva SC

Q9997

Pyzchiva IV

Q9998

Selarsdi IV and SC

Q9999

Otulfi IV and SC

Q5133

Tofidence

J1299*

Soliris

Q5151

Epysqli

Q5152

Bkemv

Q5134

Tyruko

*Applicable Site of Care (SOC) rates apply only to Home Infusion Therapy (HIT) and Ambulatory Infusion Suites (AIS) providers.

Accessing Fee Schedules

Once you log into Availity, select Claims & Payments from the task bar and then Fee Schedule Listing from the right side. You can also access fee schedules by going to Payer Spaces in Availity, and then select Provider Resource Center (PRC) under Applications. Once you arrive at the PRC, choose Claims & Authorization and then click Fee Schedule Information.

In the Spotlight